Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

LAUR Repository

Show simple item record

dc.contributor.author Taher, A.
dc.contributor.author Sheikh-Taha, M.
dc.contributor.author Koussa, S.
dc.contributor.author Inati, A.
dc.contributor.author Neeman, R.
dc.contributor.author Mourad, F.
dc.date.accessioned 2016-06-01T12:23:57Z
dc.date.available 2016-06-01T12:23:57Z
dc.date.copyright 2001 en_US
dc.date.issued 2016-06-01
dc.identifier.issn 0902-4441 en_US
dc.identifier.uri http://hdl.handle.net/10725/3921
dc.description.abstract Abstract: Introduction: Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically improved the prognosis of this disease. However, the limitations of this treatment have stimulated the design of alternative orally active iron chelators. Objective: To compare the effectiveness and safety of, and compliance with, oral deferiprone (L1), and deferoxamine, in thalassemia major patients. Methods: All patients were followed up in one center in Lebanon. Sixteen patients were on L1 (75 mg/kg/d), and 40 patients on subcutaneous deferoxamine (20–50 mg/kg/d). Serum ferritin level, urinary iron excretion (UIE) and side effects were monitored over a two year period. Results: Patients on L1 had an initial serum ferritin concentration of 3663±566 µg/l (mean±SEM), that dropped to 2599±314 at 6 months (p<0.02; paired t-test), and stabilised at that level over the 24 months follow up. Patients on deferoxamine had an initial mean serum ferritin concentration of 3480±417 (NS compared to the L1 group), which dropped gradually to 3143±417 (p<0.05) and 2819±292 (p<0.02) at 6 and 24 months, respectively. The most common adverse reactions associated with L1 were arthralgia and nausea, but they did not necessitate stopping the drug. Conclusion: L1 had comparable efficacy as deferoxamine with minimal side effects and better compliance. Provided long term side effects are not encountered, L1 seems to be a valuable alternative iron chelator for patients unable or unwilling to use deferoxamine effectively. en_US
dc.language.iso en en_US
dc.title Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 199410150 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal European Journal of Haematology en_US
dc.journal.volume 67 en_US
dc.journal.issue 1 en_US
dc.article.pages 30-34 en_US
dc.keywords Deferiprone en_US
dc.keywords Deferoxamine en_US
dc.keywords Thalassemia en_US
dc.keywords Iron chelation en_US
dc.identifier.doi http://dx.doi.org/10.1034/j.1600-0609.2001.067001030.x en_US
dc.identifier.ctation Taher, A., Sheikh‐Taha, M., Koussa, S., Inati, A., Neeman, R., & Mourad, F. (2001). Comparison between deferoxamine and deferiprone (L1) in iron‐loaded thalassemia patients. European journal of haematology, 67(1), 30-34. en_US
dc.author.email marwan.taha@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://onlinelibrary.wiley.com/doi/10.1034/j.1600-0609.2001.067001030.x/full en_US
dc.orcid.id https://orcid.org/0000-0002-8037-1201 en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account